title: Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.
abstract: OBJECTIVE
  This multicenter study examined the impact of albumin excretion rate (AER) on the course of estimated glomerular filtration rate (eGFR) and the incidence of sustained eGFR <60 ml/min/1.73 m(2) in type 1 diabetes up to year 14 of the Epidemiology of Diabetes Interventions and Complications (EDIC) study (mean duration of 19 years in the Diabetes Control and Complications Trial [DCCT]/EDIC).
  
  
  METHODS
  Urinary albumin measurements from 4-h urine collections were obtained from participants annually during the DCCT and every other year during the EDIC study, and serum creatinine was measured annually in both the DCCT and EDIC study. GFR was estimated from serum creatinine using the abbreviated Modification of Diet in Renal Disease equation.
  
  
  RESULTS
  A total of 89 of 1,439 subjects developed an eGFR <60 ml/min/1.73 m(2) (stage 3 chronic kidney disease on two or more successive occasions (sustained) during the DCCT/EDIC study (cumulative incidence 11.4%). Of these, 20 (24%) had AER <30 mg/24 h at all prior evaluations, 14 (16%) had developed microalbuminuria (AER 30-300 mg/24 h) before they reached stage 3 chronic kidney disease, and 54 (61%) had macroalbuminuria (AER >300 mg/24 h) before they reached stage 3 chronic kidney disease. Macroalbuminuria is associated with a markedly increased rate of fall in eGFR (5.7%/year vs. 1.2%/year with AER <30 mg/24 h, P < 0.0001) and risk of eGFR <60 ml/min/1.73 m(2) (adjusted hazard ratio 15.3, P < 0.0001), whereas microalbuminuria had weaker and less consistent effects on eGFR.
  
  
  CONCLUSIONS
  Macroalbuminuria was a strong predictor of eGFR loss and risk of developing sustained eGFR <60 ml/min/1.73 m(2). However, screening with AER alone would have missed 24% of cases of sustained impaired eGFR.
authors.affiliation: Northwestern University, Chicago, Illinois, USA. cleary@biostat.bsc.gwu.edu
authors.forename: Mark E
authors.initials: ME
authors.lastname: Molitch
authors.forename: Michael
authors.initials: M
authors.lastname: Steffes
authors.forename: Wanjie
authors.initials: W
authors.lastname: Sun
authors.forename: Brandy
authors.initials: B
authors.lastname: Rutledge
authors.forename: Patricia
authors.initials: P
authors.lastname: Cleary
authors.forename: Ian H
authors.initials: IH
authors.lastname: de Boer
authors.forename: Bernard
authors.initials: B
authors.lastname: Zinman
authors.forename: John
authors.initials: J
authors.lastname: Lachin
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000453:epidemiology* / Q000503:physiopathology; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000453:epidemiology* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D015994:Incidence; D008297:Male; D015337:Multicenter Studies as Topic; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D003404:Creatinine